Navigation Links
DARA Announces Information in Compliance with NASDAQ Rules
Date:4/7/2008

RALEIGH, N.C., April 7, 2008 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today that the audit report accompanying the financial statements for the fiscal year ended December 31, 2007, as included in the Company's Annual Report on 10-K filed on March 31, 2008, contained a going concern qualification. NASDAQ Marketplace Rule 4350(b)(1)(B) requires that a public announcement be made regarding the receipt of an audit opinion that contains a going concern qualification.

In making the announcement, John C. Thomas, Jr., Chief Financial Officer, noted, "Given the financials for the year ended December 31, 2007 reflect Point Therapeutics' operating results and financial position prior to the merger with DARA BioSciences, the going concern qualification was expected. The merger with DARA BioSciences occurred on February 12, 2008 and the first reported results of the merged entity will be on Form 10-Q for the quarter ending March 31, 2008. With that said, it is also important to note that DARA has previously stated that it does intend to seek additional capital during the coming year."

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders.

DARA trades on the NASDAQ Global Market under the ticker symbol "DARA".

For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others, the company's ability to raise capital, and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.


'/>"/>
SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
2. VA Announces SGLI and VGLI Premium Reductions
3. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
4. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
5. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
6. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
7. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
8. Smart Balance Announces Sales Organization Appointments
9. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
10. NTMir Announces First International Research Grant for Genome Sequencing
11. Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a ... and adults with muscular dystrophy, ALS and related diseases that severely limit strength ...
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced ... and donate to Give To Cure’s campaign that is crowdfunding clinical trials to help ... and share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion ...
(Date:2/5/2016)... ... 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled to ... the most effective tattoo removal today, Dr. Bentkover is the only doctor in Central ... the PicoSure has been approved by the Food and Drug Administration (FDA) as a ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... a medical devices company, is one of five recipients to ... Terry McAuliffe,s office. ivWatch will be receiving the STEM ... to be held at the Science Museum of ... that have made significant contributions to science. ... ivWatch ...
(Date:2/5/2016)... Feb. 5, 2016 ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ...
(Date:2/5/2016)... BEIJING , Feb. 5, 2016 ... ("Dehaier Medical" or the "Company"), which develops, markets ... products in China and ... restructuring plan which aims to concentrate the Company,s ... wearable sleep respiratory business and to focus more ...
Breaking Medicine Technology: